CAS:108605-62-5Teriflunomide(Random Configuration)

您的位置 : 首页 / Metabolic Enzyme / Dehydrogenase / Teriflunomide(Random Configuration)

Teriflunomide(Random Configuration) 2-氰基-3-羟基-N-(4-(三氟甲基)苯基)丁-2-烯酰胺 Cat No. FB10488Cas No. 108605-62-5

Synonyms: A77 1726(Random Configuration);HMR 1726(Random Configuration)

Teriflunomide, the active metabolite of an approved antirheumatic drug leflunomide, is an emerging oral therapy for multiple sclerosis (MS). It reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 3.7009 mL
- 18.5043 mL
- 37.0086 mL
- 5 mM
- 0.7402 mL
- 3.7009 mL
- 7.4017 mL
- 10 mM
- 0.3701 mL
- 1.8504 mL
- 3.7009 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号	108605-62-5	储存条件	粉末 -20°C 3 年液体 -80°C 12 月
分子式	C12H9F3N2O2	运输	蓝冰
分子量	270.21	别名	A77 1726(Random Configuration);HMR 1726(Random Configuration)

靶点数据

生物活性

描述Teriflunomide (Random Configuration) is a disease-modifying immunomodulatory drug with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydro-orotate dehydrogenase, with consequent inhibition of de novo pyrimidine synthesis and reduced lymphocyte proliferation. Oral teriflunomide is an effective and generally well tolerated treatment in patients with relapsing multiple sclerosis (MS)^[3]. Effects on time to failure were comparable between teriflunomide and IFNβ-1a. There was no difference between teriflunomide (14 mg) and IFNβ-1a on ARR (annualised relapse rate), though ARR was higher with teriflunomide (7 mg)^[4]. Low teriflunomide concentrations resulted in cell cycle exit while higher doses led to decreased cell survival. Short-term teriflunomide pulses can efficiently promote oligodendroglial cell differentiation suggesting that young, immature cells could benefit from such stimulation. In vitro myelination can be boosted by means of an early stimulation window with teriflunomide^[5].